[Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events].

Abstract

OBJECTIVES:

To establish the efficiency and adverse effects of the addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection.

MATERIAL AND METHODS:

Double blind controlled experimental trial. The study population consisted of 54 patients with Helicobacter pylori infection: 29 were allocated to the experimental group, who received the usual triple plus bismuth subsalicylate therapy, and 24 received the triple therapy plus placebo.

RESULTS:

The average age was 47+-14.9 years, 66.7% of the patients were women. Both groups underwent the breath test: it was negative in 89.7% of the patients from the experimental group and 80% of the patients from the placebo group (p=0.319). The adverse events of both groups were: diarrhea (10.3% in the experimental group vs 16% in the placebo group; p=0.537), dark feces (37.9% in the experimental group vs 0% in the placebo group; p=0.001), abdominal pain (20.7% in the experimental group vs 52% in the placebo group; p=0.016). Nausea only were present in 3% of the patients of placebo group p=0.055).

CONCLUSIONS:

The association of bismuth subsalicylate to the triple therapy scheme for the eradication of Helicobacter pylori was effective in 89.7% of patients, whereas 80% of efficiency in the experimental group.

• Authors: Dennis Hinostroza Morales, Javier Díaz Ferrer
• Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru (Rev Gastroenterol Peru) 2014 Oct-Dec Vol. 34 Issue 4 Pg. 315-20 ISSN: 1609-722X [Electronic] Peru
• Vernacular Title: Adición de subsalicilato de Bismuto a la terapia triple erradicadora de la infección por Helicobacter pylori: efectividad y efectos adversos.
• PMID: 25594755 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Bacterial Agents
• Organometallic Compounds
• Proton Pump Inhibitors
• Salicylates
• bismuth subsalicylate
• Amoxicillin
• Clarithromycin
• Omeprazole
• Bismuth

Topics

• Adult
• Aged
• Amoxicillin (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Bismuth (therapeutic use)
• Clarithromycin (therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Helicobacter Infections (drug therapy)
• Helicobacter pylori
• Humans
• Male
• Middle Aged
• Omeprazole (therapeutic use)
• Organometallic Compounds (therapeutic use)
• Proton Pump Inhibitors (therapeutic use)
• Salicylates (therapeutic use)
• Treatment Outcome